CardioRenal Systems is a medical-device company developing automated fluid-management technology to protect kidney function during high-risk hospital procedures. Its console measures urine output and adjusts physician-prescribed intravenous hydration to replace fluid losses, using disposable infusion and urine-collection sets. The technology is branded RenalPro in the United States and RenalGuard internationally, with development focused on preventing acute kidney injury associated with cardiac surgery and other cardiovascular interventions. CardioRenal Systems, Inc., based in Milford, Massachusetts, is identified in the current operator manual as the manufacturer and parent of RenalGuard Solutions, Inc. The company reports that RenalGuard is CE marked for fluid-balance management outside the United States. RenalPro remains investigational in the United States; the company’s July2026 announcement reports FDA permission to conduct a pivotal cardiac-surgery trial, rather than marketing authorization.
